A new company called SciNeuro Pharmaceuticals, started in 2020, announced on Thursday that it has raised $53 million to help develop medicines for diseases that damage nerves. This money comes from investors like Arch Venture Partners and a Chinese company called LAV, along with other new and existing investors. SciNeuro plans to use this money to advance its drug programs, which aim to treat diseases like Alzheimer’s and Parkinson’s. Along with this funding, SciNeuro also welcomed Hogan Wan as its new chief financial officer. Wan has over a decade of experience in finance and investment in the biopharmaceutical industry and previously worked at Ascentage Pharma, where he helped the company go public. Arch Venture Partners is known for investing in young biotechnology companies. Since 2022, they have participated in at least 74 funding rounds, including 13 in 2025 alone. They raised $3 billion last year to continue investing in startups. SciNeuro is one of their recent investments focused on the nervous system, an area of drug development known for its challenges and low success rates. Other companies Arch has invested in recently include Aspen Neuroscience and Tenvie Therapeutics. SciNeuro is working on creating new treatments that target specific proteins linked to diseases like Alzheimer’s and Parkinson’s. They have also received a $5 million grant from The Michael J. Fox Foundation for Parkinson’s Research. The company’s founder and CEO, Min Li, said that this funding is a significant achievement for SciNeuro and shows their commitment to advancing treatments for nerve diseases.